Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacobo Mintzer

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|October 19, 2018
Perspective from Clinical Research: Ethical Issues in Alzheimer's Disease ResearchJacobo Mintzer
Current Opinion in Psychiatry|October 9, 2007
The many faces of psychosis in the elderlyJessica Broadway, Jacobo Mintzer
Expert Review of Neurotherapeutics|October 22, 2011
Depression in Alzheimer's disease: consequence or contributing factor?Jacobo Mintzer, Courtney O'Neill
Journal of Geriatric Psychiatry and Neurology|December 5, 2003
Psychosis in elderly patients: classification and pharmacotherapyJacobo Mintzer, Steven D Targum
Dialogues in Clinical Neuroscience|October 29, 2011
Combination pharmacotherapy in Alzheimer's diseaseJacobo Mintzer, Dena Armstrong, Warachal E Faison
International Psychogeriatrics|October 11, 2018
A retrospective, population-based cohort study of driving under the influence, Alzheimer's disease diagnosis, and survivalMargaret Miller, Dennis Orwat, Gelareh Rahimi, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2009
Commentary: "Ceramide and cholesterol: possible connections between normal aging of the brain and Alzheimer's disease. Just hypotheses or molecular pathways to be identified?" by Claudio Costantini, Rekha M.K. Kolasani, Luigi PuglielliAnn-Charlotte Granholm, David Bachman, Jacobo Mintzer, et al.
Clinical Drug Investigation|April 15, 2008
A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's diseaseStephanie Kirbach, Kit Simpson, Paul J Nietert, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 18, 2008
Disease-modifying therapies in Alzheimer's diseaseStephen Salloway, Jacobo Mintzer, Myron F Weiner, et al.
Journal of Clinical Medicine|January 25, 2025
Neuroinflammation: A Driving Force in the Onset and Progression of Alzheimer's DiseaseCampbell Long, Arianne Fritts, Jessica Broadway, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|October 19, 2018
Perspective from Clinical Research: Ethical Issues in Alzheimer's Disease ResearchJacobo Mintzer
Current Opinion in Psychiatry|October 9, 2007
The many faces of psychosis in the elderlyJessica Broadway, Jacobo Mintzer
Expert Review of Neurotherapeutics|October 22, 2011
Depression in Alzheimer's disease: consequence or contributing factor?Jacobo Mintzer, Courtney O'Neill
Journal of Geriatric Psychiatry and Neurology|December 5, 2003
Psychosis in elderly patients: classification and pharmacotherapyJacobo Mintzer, Steven D Targum
Dialogues in Clinical Neuroscience|October 29, 2011
Combination pharmacotherapy in Alzheimer's diseaseJacobo Mintzer, Dena Armstrong, Warachal E Faison
International Psychogeriatrics|October 11, 2018
A retrospective, population-based cohort study of driving under the influence, Alzheimer's disease diagnosis, and survivalMargaret Miller, Dennis Orwat, Gelareh Rahimi, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2009
Commentary: "Ceramide and cholesterol: possible connections between normal aging of the brain and Alzheimer's disease. Just hypotheses or molecular pathways to be identified?" by Claudio Costantini, Rekha M.K. Kolasani, Luigi PuglielliAnn-Charlotte Granholm, David Bachman, Jacobo Mintzer, et al.
Clinical Drug Investigation|April 15, 2008
A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's diseaseStephanie Kirbach, Kit Simpson, Paul J Nietert, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 18, 2008
Disease-modifying therapies in Alzheimer's diseaseStephen Salloway, Jacobo Mintzer, Myron F Weiner, et al.
Journal of Clinical Medicine|January 25, 2025
Neuroinflammation: A Driving Force in the Onset and Progression of Alzheimer's DiseaseCampbell Long, Arianne Fritts, Jessica Broadway, et al.
Pageof 7